<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728828</url>
  </required_header>
  <id_info>
    <org_study_id>COVADIAL</org_study_id>
    <nct_id>NCT04728828</nct_id>
  </id_info>
  <brief_title>COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients</brief_title>
  <acronym>COVADIAL</acronym>
  <official_title>Immune Response After COVID19 Vaccination in a Multicenter Cohort of In-center Haemodialysis Patients in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Cornouaille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Régional et Universitaire de Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier de Cornouaille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a severe disease with poor prognosis in patients receiving in-center&#xD;
      haemodialysis (HD). A population-based registry of &gt;4,000 patients with a diagnosis of&#xD;
      COVID-19 receiving kidney replacement therapy (either haemodialysis or kidney transplant&#xD;
      recipient) highlighted a 21.1 fold higher 28-day mortality risk among patients on dialysis (n&#xD;
      = 3,285), than the expected 1.2% mortality of propensity-score matched historical controls.&#xD;
      Vulnerability in uraemic patients is a combination of intrinsic frailty, increased risk of&#xD;
      infection and a high burden of comorbidities. In patients on HD, abnormalities in the immune&#xD;
      response may contribute to relative hyporesponsiveness to vaccines. However, patients on HD&#xD;
      appear to seroconvert at a similar rate compared to the general population after SARS-CoV-2&#xD;
      infection, suggesting a likelihood of vaccine efficacy but this population has been excluded&#xD;
      from vaccine trials. The primary aim of this study is to evaluate antibody synthesis induced&#xD;
      after Covid-19 vaccination in a French adult multicentric cohort of in-center haemodialysis&#xD;
      patients. The second aim of this study is to identify vaccine non-responders among HD&#xD;
      patients and to assess the clinical and biological risk factors associated with non-response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients were excluded from COVID19 vaccine response studies: seroprotection&#xD;
      rate? Long-term protection? Different regimens to offer to hemodialysis patients?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>day 0</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>before 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>1 month after 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>3 month after 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>6 month after 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>12 month after 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibody synthesis induced after Covid-19 vaccination</measure>
    <time_frame>24 month after 2nd injection</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lack of immunogenicity</measure>
    <time_frame>day 0, before 2nd injection, 1 month after reinjection, 3 months after reinjection, 6 months, 12 months, 24 months</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events after vaccination</measure>
    <time_frame>day 0, before 2nd injection, 1 month after reinjection, 3 months after reinjection, 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 incidence</measure>
    <time_frame>day 0, before 2nd injection, 1 month after reinjection, 3 months after reinjection, 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death during follow up</measure>
    <time_frame>day 0, before 2nd injection, 1 month after reinjection, 3 months after reinjection, 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure antibody response to vaccines in patient subgroup (diabetic patients, patients with auto-immune disease, patients with cancer, patients with an history of solid organ transplantation)</measure>
    <time_frame>day 0, before 2nd injection, 1 month after reinjection, 3 months after reinjection, 6 months, 12 months, 24 months</time_frame>
    <description>evaluation of IgG anti-S level</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hepatitis B-vaccination response</measure>
    <time_frame>Day 0</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serological COVID-19 vaccine immunogenicity</intervention_name>
    <description>Serological test</description>
    <arm_group_label>In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all in-center haemodialysis patients eligible to receive one of the approved&#xD;
        SARS-CoV-2/COVID-19 vaccines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all in-center haemodialysis individuals eligible and voluntary to receive one of the&#xD;
             approved COVID-19 vaccines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals under 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier de Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Loheac, MD</last_name>
      <phone>+33 2 90 94 41 69</phone>
      <email>charlotte.loheac@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, Collart F, Hemmelder MH, Ambühl P, Kerschbaum J, Legeai C, Del Pino Y Pino MD, Mircescu G, Mazzoleni L, Hoekstra T, Winzeler R, Mayer G, Stel VS, Wanner C, Zoccali C, Massy ZA. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020 Dec;98(6):1540-1548. doi: 10.1016/j.kint.2020.09.006. Epub 2020 Oct 15.</citation>
    <PMID>32979369</PMID>
  </results_reference>
  <results_reference>
    <citation>ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94. doi: 10.1093/ndt/gfaa314.</citation>
    <PMID>33340043</PMID>
  </results_reference>
  <results_reference>
    <citation>Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007 Sep-Oct;20(5):440-51. Review.</citation>
    <PMID>17897251</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahalingasivam V, Tomlinson L. The seroprevalence of SARS-CoV-2 in patients on haemodialysis. Nat Rev Nephrol. 2020 Nov 23. doi: 10.1038/s41581-020-00379-y. [Epub ahead of print]</citation>
    <PMID>33230249</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Vaccine response</keyword>
  <keyword>Serology</keyword>
  <keyword>haemodialysis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

